Genovate Biotechnology Co., Ltd. (TPEX:4130)

Market Cap	3.83B
Revenue (ttm)	491.23M
Net Income (ttm)	10.93M
Shares Out	113.75M
EPS (ttm)	0.10
PE Ratio	350.33
Forward PE	n/a
Dividend	0.10 (0.29%)
Ex-Dividend Date	Aug 20, 2025

Volume	867,829
Average Volume	3,349,293
Open	34.30
Previous Close	33.65
Day's Range	33.40 - 34.50
52-Week Range	17.65 - 40.15
Beta	0.25
RSI	62.43
Earnings Date	Mar 26, 2026

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1982
• Employees: 195
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4130

Financial Performance

In 2024, Genovate Biotechnology's revenue was 510.86 million, a decrease of -3.34% compared to the previous year's 528.51 million. Earnings were 25.70 million, a decrease of -12.40%.